Trial reportBMC geriatrics2015
The protocol of the Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial.
Trial report in BMC geriatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01956604 (The Oslo Study of Clonidine in Elderly Patients With Delirium), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Oslo Study of Clonidine in Elderly Patients With Delirium
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Association between components of the delirium syndrome and outcomes in hospitalised adults: a systematic review and meta-analysis.BMC geriatrics · 2021Pooled it
- A randomized pilot and feasibility trial of live and recorded music interventions for management of delirium symptoms in acute geriatric patients.BMC geriatrics · 2025Trial
- The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses.BMC pharmacology & toxicology · 2018Trial
- Increased cerebrospinal fluid YKL-40 concentration in hip fracture patients with delirium.Brain communications · 2026Article
- Clonidine for Management of Agitation in Delirious Patients.Current psychiatry reports · 2025Review
- Differences in metalloproteinases and their tissue inhibitors in the cerebrospinal fluid are associated with delirium.Communications medicine · 2024Article
- Article
- Orthogeriatric co-management reduces incidence of delirium in hip fracture patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Observational
- Comparative evaluation of oral melatonin and oral clonidine for the attenuation of haemodynamic response to laryngoscopy and tracheal intubation-A prospective randomised double blind study.Indian journal of anaesthesia · 2020Article
- A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- The neuropsychology of delirium: advancing the science of delirium assessment.International journal of geriatric psychiatry · 2018Review
- How do doctors and nurses manage delirium in intensive care units? A qualitative study using focus groups.BMJ open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundDelirium affects 15% of hospitalised patients and is linked with poor outcomes, yet few pharmacological treatment options exist. One hypothesis is that delirium may in part result from exaggerated and/or prolonged stress responses. Dexmedetomidine, a parenterally-administered alpha2-adrenergic receptor agonist which attenuates sympathetic nervous system activity, shows promise as treatment in ICU delirium. Clonidine exhibits similar pharmacodynamic properties and can be administered orally. We therefore wish to explore possible effects of clonidine upon the duration and severity of delirium in general medical inpatients. METHODS/
designThe Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is a randomised, placebo-controlled, double-blinded, parallel group study with 4-month prospective follow-up. We will recruit 100 older medical inpatients with delirium or subsyndromal delirium in the acute geriatric ward. Participants will be randomised to oral clonidine or placebo until delirium free for 2 days (Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria), or after a maximum of 7 days treatment. Assessment of haemodynamics (blood pressure, heart rate and electrocardiogram) and delirium will be performed daily until discharge or a maximum of 7 days after end of treatment. The primary endpoint is the trajectory of delirium over time (measured by Memorial Delirium Assessment Scale). Secondary endpoints include the duration of delirium, use of rescue medication for delirium, pharmacokinetics and pharmacodynamics of clonidine, cognitive function after 4 months, length of hospital stay and need for institutionalisation. DISCUSSION: LUCID will explore the efficacy and safety of clonidine for delirium in older medical inpatients.
trial registrationClinicalTrials.gov NCT01956604. EudraCT Number: 2013-000815-26.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.